UNSPSC 51282943: Rufloxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H18FN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y521XM2900, chemically known as 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid but generally known as rufloxacin, which bears US NIH Compound Identifier 58258. European Medicines Agency schedules Rufloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10404MIG.

UNSPSC 51282943 Rufloxacin, a Commodity code, shows limited recent activity directly aligned with the pharmaceutical product itself. The recent state and local opportunities tagged under this code predominantly solicit broader medical supplies, pharmaceuticals, and pharmacy benefit management services rather than rufloxacin specifically. Seminole County, Florida's IFB for naloxone and drug deactivation systems, the City of Tampa's medical and first aid supplies procurement for fire rescue operations, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products represent the scope of actual buying activity. These solicitations span emergency response supplies, fire department medical equipment, and cooperative purchasing arrangements for generic pharmaceutical distribution — none of which targets rufloxacin as a line item or primary deliverable. The issuing bodies include county health departments, municipal fire divisions, and state-level cooperative purchasing organizations serving multiple jurisdictions.

Recent activity is concentrated in Florida and the upper Midwest. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) and Tampa's medical supplies bid (26P00145, due March 13, 2026, estimated $700,000 and sheltered for certified Small Local Business Enterprises) represent municipal and county health and emergency response buying. The Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals (S1070000015802, due March 26, 2026) spans participating states including Oregon and serves state and local government facilities through three authorized wholesalers. The Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescriptions (HHS0017013, posted April 3, 2026) indicates exploratory procurement strategy development rather than a committed solicitation. The code shows no concentrated activity around rufloxacin as a named product and warrants characterization as a low-relevance match for vendors targeting that specific pharmaceutical.